|Articles|June 1, 1998

June 1998
Volume 4
Issue 6

A Pharmacoeconomic Analysis of Rimelolone for the Treatment of Ophthalmic Inflammatory Conditions

Author(s)Michael T. Halpern, MD, PhD, Cynthia S. Palmer, MSc, C. Stephen Foster, MD

Download PDF: A Pharmacoeconomic Analysis of Rimelolone for the Treatment of Ophthalmic Inflammatory Conditions

Articles in this issue

over 27 years ago

Article

Correspondence regarding, "Screening and Surveillance for Colorectal Cancer"

over 27 years ago

Article

"Carving Out" Conditions From Global Capitation Rates: Protecting High-Cost Patients, Physicians, and Health Plans in a Managed Care Environment

over 27 years ago

Article

Delivery of Preventive Healthcare to Older African-American Patients: A Performance Comparison from Two Practice Models

over 27 years ago

Article

Insurance Type and the Transportation to Emergency Departments of Patients with Acute Cardiac Ischemia: The ACI-TIPI Trial Insurance Study

over 27 years ago

Article

Does Competition by Health Maintenance Organizations Affect the Adoption of Cost-Containment Measures by Fee-for-Service Plans?

over 27 years ago

Article

Safety and Clinical Efficacy of Zileuton in Patients with Chronic Asthma

over 27 years ago

Article

Identification and Case Management in an HMO of Patients at Risk of Preterm Labor

over 27 years ago

Article

A Closer Look at Lower Back Pain

over 27 years ago

Article

Food Borne Illnesses in the United States: Office Recognition and Management

over 27 years ago

Article

Rheumatoid Arthritis: Focus on Appropriate Drug Therapy

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Subscribe Now!

Related Content

HEDIS Glycemic Goal Achieved Using Control-IQ Technology

ByBimal V. Patel, PharmD, MS,Sharon M. Wang, PharmD, MS,Laurel H. Messer, PhD, MPH, RN, CDCES, BC-ADM,Jordan E. Pinsker, MD,Miranda R. Polin, MS, BS,Irl B. Hirsch, MD,Laya Ekhlaspour, MD,Steve Edelman, MD,Diana I. Brixner, PhD, RPh,Charles Stemple, DO

December 22nd 2025

Linking Data to Determine Risk for 30-Day Readmissions in Dementia

ByPamela S. Roberts, PhD, OTR/L,Chih-Ying Li, PhD, OTR/L,Debra S. Ouellette, MS, OTR/L,Nabeel Qureshi, MPH,Erica Spivack, MHA,Mary Nasmyth, MD,Nancy L. Sicotte, MD,Zaldy S. Tan, MD

December 22nd 2025

Performance of 2-Stage Health-Related Social Needs Screening Using Area-Level Measures

ByJoshua R. Vest, PhD, MPH,Christopher A. Harle, PhD,Justin Blackburn, PhD

December 19th 2025

Impact of Medicaid Institution for Mental Diseases Exclusion on Serious Mental Illness Outcomes

ByOnur Baser, PhD, MS,Heidi C. Waters, PhD,Nehir Yapar, BS,Katarzyna Rodchenko, MA, MPH,Lauren Isenman, MPH,Xue Han, PhD,Deborah Freedman, MBA,Rashmi Patel, MD, PhD

December 17th 2025

Physician-Pharmacy Integration in Cancer Care: Pillars of Medically Integrated Pharmacy

ByGury K. Doshi, MD,Lucio Gordan, MD,Kirollos Hanna, PharmD,Scott Freeswick, PharmD,Natalie Dickson, MD,Desi Kotis, PharmD,Osama Abdelghany, PharmD, MHA,Ken Komorny, PharmD,Neal Dave, PharmD,Michael Reff, RPh, MBA

December 16th 2025

A Pharmacoeconomic Analysis of Rimelolone for the Treatment of Ophthalmic Inflammatory Conditions

Articles in this issue

Newsletter

Related Content

HEDIS Glycemic Goal Achieved Using Control-IQ Technology

Linking Data to Determine Risk for 30-Day Readmissions in Dementia

Performance of 2-Stage Health-Related Social Needs Screening Using Area-Level Measures

Impact of Medicaid Institution for Mental Diseases Exclusion on Serious Mental Illness Outcomes

Physician-Pharmacy Integration in Cancer Care: Pillars of Medically Integrated Pharmacy

Trending on AJMC

Top 5 Most-Read Cardiovascular Content of 2025

Meta-Analysis Supports RSV Vaccine Efficacy and Safety in Older Adults

Top 5 Most-Read SAP Content in 2025

Top 5 Trending FDA Approvals of 2025

Top 5 Most-Read Multiple Sclerosis Articles of 2025